Inflammation and Psoriasis: Understanding the Science Behind the Skin

Psoriasis is often described as a skin disease, but that description undersells what’s actually happening beneath the surface. At its core, psoriasis is a disease of inflammation, and understanding that inflammation is the key to understanding almost everything else about the condition.

This guide explains what inflammation actually is in the context of psoriasis, how it spreads beyond the skin, and what current research says about calming it through both medical treatment and lifestyle factors.

What Inflammation Actually Means in Psoriasis

Inflammation is, at its most basic level, the immune system’s response to a perceived threat. In psoriasis, that response fires even though there’s no real infection or injury to fight, and it doesn’t know how to switch itself back off.

The Innate and Adaptive Immune Systems, Working Together

Psoriasis results from a breakdown in communication between two branches of the immune system that are normally supposed to work in balance. The pathologic collaboration between innate immunity, mediated by antigen-presenting cells and natural killer T lymphocytes, and acquired immunity, mediated by T lymphocytes, results in the production of cytokines, chemokines, and growth factors that build up in psoriatic plaques.

Innate immunity is the body’s fast, general-purpose first responder system. Innate immune cells orchestrate the initial response in psoriasis by detecting danger signals and amplifying inflammation to engage adaptive immune components, involving dendritic cells, macrophages, and several other specialized cell types.

Adaptive immunity, primarily driven by T cells, then takes over and sustains the inflammatory response over time. Innate lymphoid cells, γδ T cells, natural killer T cells, and natural killer cells are activated in psoriasis, contributing to disease pathology through IL-17-dependent and independent mechanisms, showing just how many different immune cell types participate in the process.

Why the Inflammation Doesn’t Switch Off

In a healthy immune response, inflammation resolves once a threat is cleared. In psoriasis, several of the body’s normal braking mechanisms appear to be impaired.

T-regulatory cell suppressor activity in skin lesions and in blood is deficient, which may be permissive for unrestrained T-cell proliferation, along with chronic overproduction of chemokines and Th1-derived cytokines such as interferon-gamma, interleukin-2, and TNF-alpha. Regulatory T cells normally act as a built-in brake on immune activity, so their reduced function helps explain why psoriatic inflammation persists rather than resolving on its own.

How Inflammation Directly Builds the Plaque

This immune activity doesn’t stay abstract; it directly reshapes the skin itself. Overproduction of inflammatory cytokines and growth factors targets epidermal keratinocytes, causing them to hyperproliferate, develop an abnormal terminal differentiation program, and become resistant to normal cell-death signals.

Blood vessel changes reinforce this cycle further. This epidermal hyperproliferation is supported by neoangiogenesis, the formation of new blood vessels, which is also driven by T-cell-derived inflammatory cytokines, helping explain the visible redness of active plaques.

A Newer Model: The “Immune Set-Point”

Recent research has proposed a more sophisticated way of understanding why psoriasis behaves the way it does over time, including why it relapses even after skin appears clear. This model helps explain patterns that a simple “on or off” view of inflammation doesn’t fully capture.

Chronic Priming, Not Just Isolated Flares

Emerging evidence supports a model in which impaired immune tolerance and sustained activation of systemic immune responses establish a state of chronic inflammatory priming, according to a 2026 framework published in Frontiers in Immunology. Rather than the body being either fully triggered or fully at rest, this model describes a persistently elevated baseline of immune readiness.

This shows up biologically in several interconnected ways. In plaque psoriasis, regulatory T-cell dysfunction, enhanced dendritic cell activation, and heightened responsiveness of the IL-23-IL-17 pathway weaken mechanisms that normally restrain inflammatory amplification, while metabolic and functional changes occur in both innate and adaptive immune cell populations.

Why This Matters for Understanding Relapse

This framework offers a compelling explanation for a pattern many patients experience firsthand: psoriasis returning even after a period of genuinely clear skin. These changes are more consistent with persistent elevation of the systemic immune set-point than with a transient episode of inflammatory overactivation, suggesting that some degree of immune readiness for relapse may linger even during remission.

This is also part of why the treat-to-target approach discussed in our “Creating Treatment Goals” guide emphasizes sustained, ongoing treatment rather than treating psoriasis as a series of isolated episodes. If the underlying immune set-point remains elevated, stopping treatment as soon as skin clears may simply be treating the visible symptom rather than the underlying biological state.

Why Psoriasis Is a Whole-Body Inflammatory Disease

Because the inflammatory drivers behind psoriasis circulate through the bloodstream rather than staying confined to the skin, their effects show up in organs far from any visible plaque. This is the central reason psoriasis is now classified as a systemic inflammatory disease rather than a purely dermatologic one.

Measurable Inflammation in the Blood

Inflammation in psoriasis isn’t just a theoretical concept; it can be measured directly through blood testing. Analysis of psoriatic patients has revealed significantly higher levels of CRP, Lp-PLA2, leptin, and resistin compared to healthy controls, reflecting genuine, circulating systemic inflammation rather than skin-limited activity.

Researchers have also identified newer, more sensitive markers specific to psoriasis. Serum YKL-40 concentration was significantly higher in psoriatic patients than in controls, elevated in 81.8% of patients compared to just 20% for CRP, making it a more sensitive biomarker of systemic inflammation than CRP or white blood cell count.

The Cardiovascular Connection

This circulating inflammation has direct, measurable downstream effects on blood vessels, tying directly into the psoriatic march concept covered in our pillar guide. Elevated Lp-PLA2 levels specifically indicate the presence of subclinical atherosclerosis, representing genuine cardiovascular risk, in psoriatic patients, even before any cardiovascular symptoms appear.

Lung and Respiratory Involvement

Less commonly discussed, but increasingly well documented, is a connection between psoriasis and respiratory disease. The development of lung diseases in patients with psoriasis can be explained by several mechanisms, including common risk factors, shared immune and molecular characteristics associated with chronic inflammation, and other overlapping mechanisms, according to a systematic review examining conditions like asthma, COPD, and pulmonary hypertension in psoriasis patients.

Metabolic Tissue Is Both Affected and Involved

The relationship between psoriasis and metabolic health runs in both directions, not simply psoriasis causing metabolic changes. The level of adiponectin, an anti-inflammatory hormone produced by fat tissue, was found to be significantly lower in psoriatic patients with metabolic syndrome, showing that fat tissue itself becomes an active, dysfunctional participant in the broader inflammatory picture.

Can Diet Influence Psoriatic Inflammation?

This is one of the most commonly asked questions by patients, and the honest answer is more nuanced than most headlines suggest. Some dietary patterns have reasonably solid supporting evidence, while others remain genuinely uncertain.

The Anti-Inflammatory Diet Concept

Nutrition researchers use a specific framework for measuring how inflammatory or anti-inflammatory a diet pattern actually is. Fatty acids are key players for immunomodulation, with n-3 polyunsaturated fatty acids having the most beneficial effect, while polyphenols and carotenoids seem to be the most promising antioxidants for reducing chronic inflammation and oxidative stress.

The Fish Oil Question: Genuinely Mixed Evidence

Fish oil and omega-3 supplementation is probably the most heavily studied dietary intervention in psoriasis, and it’s worth being honest about what the research actually shows rather than overselling it. Studies involving fish oil supplementation for psoriasis have produced inconsistent results, with five randomized controlled trials finding a benefit and eight finding no significant benefit compared to control treatment.

When researchers pooled the highest-quality available data, the overall result was disappointing. A meta-analysis of three randomized controlled trials involving 337 participants found that fish oil supplement did not significantly reduce psoriasis severity as measured by PASI score.

That said, more recent analysis suggests dosing and duration may matter considerably. A meta-analysis focused specifically on n-3 fatty acids as monotherapy found significant improvements in PASI score, erythema, and scaling, with subgroup analysis showing that higher doses exceeding 1,800 mg per day and shorter durations under 8 weeks were associated with more favorable results. This suggests fish oil’s effect, if real, may be modest, dose-dependent, and easy to miss in studies using lower doses or measuring over longer periods.

Weight Loss and Caloric Reduction Show More Consistent Promise

Unlike fish oil, the evidence connecting weight management to reduced psoriatic inflammation is considerably more consistent. Low-calorie diets have been shown to improve response to cyclosporine treatment in obese patients with moderate-to-severe psoriasis, with researchers pointing to reduced inflammatory activity in fat tissue as the likely mechanism.

The biological explanation for this connection is well established. Weight loss likely improves psoriasis by ameliorating obesity-induced inflammation, through decreasing the size and inflammatory activity of hypertrophic fat cells, reducing macrophage infiltration of adipose tissue, and lowering the secretion of pro-inflammatory cytokines. This lines up directly with the obesity-related content covered in our “What Causes Psoriasis?” guide.

Protein Intake: An Open Question

Some patients ask specifically about protein intake, and here the evidence is genuinely underdeveloped. Large-scale studies on the association between long-term habitual protein intake and circulating inflammatory biomarkers are lacking, though one trial found patients on low-protein diets achieved a modestly greater reduction in high-sensitivity CRP than those on high-protein diets after eight weeks.

The Honest Bottom Line on Diet

No single food or supplement reliably clears psoriasis, and claims suggesting otherwise should be treated with real skepticism. The more defensible, evidence-supported takeaway is that an overall anti-inflammatory dietary pattern, combined with achieving a healthy body weight where relevant, appears to modestly support inflammation control alongside, not instead of, medical treatment.

Sleep and Inflammation: A Two-Way Relationship

Sleep and inflammation are connected in both directions, and this bidirectional relationship is particularly relevant for a condition like psoriasis, where itching and discomfort commonly disrupt sleep in the first place.

How Poor Sleep Raises Inflammatory Markers

The connection between insufficient sleep and elevated inflammation is well established across a large body of general research. A meta-analysis of 72 studies with a combined sample size exceeding 50,000 participants found that sleep disturbance was associated with higher levels of CRP and IL-6, while shorter sleep duration was specifically associated with elevated CRP.

Timing appears to matter just as much as total duration. Adolescents who went to bed at or later than midnight showed dysregulated levels of inflammatory biomarkers, suggesting that disrupted circadian rhythm can trigger higher systemic inflammation, independent of how many total hours of sleep they got.

Why This Creates a Difficult Cycle for Psoriasis Patients

This research has direct relevance to a pattern many psoriasis patients recognize. Itchy, uncomfortable plaques disrupt sleep, and disrupted sleep appears to elevate the same inflammatory markers that drive psoriasis activity, creating a self-reinforcing loop that can be genuinely difficult to break without addressing both sides directly.

This is part of why our pillar guide’s psychological aspects section emphasizes sleep disturbance as a clinically meaningful issue in psoriasis, not simply an inconvenience. Treating the underlying skin inflammation effectively is often the most direct way to interrupt this cycle, alongside standard sleep hygiene measures.

Exercise and Inflammation

Physical activity is one of the more consistently promising, if under-discussed, tools for managing systemic inflammation generally. While psoriasis-specific human trials remain limited, the broader inflammatory science provides a reasonably strong rationale.

The General Anti-Inflammatory Effect of Exercise

Animal research has demonstrated a fairly direct anti-inflammatory effect from regular physical activity. Physical exercise induces neuroprotection through anti-inflammatory effects, and a study examining sleep-deprived rats found that exercise training attenuated markers of inflammation compared to sedentary sleep-deprived controls.

Why This Matters for Psoriasis Specifically

Given psoriasis’s documented connection to obesity and metabolic inflammation, discussed above and in our “What Causes Psoriasis?” guide, exercise’s role in weight management provides a second, complementary pathway toward reduced inflammatory burden. Regular physical activity that supports a healthy body weight is one of the more evidence-aligned lifestyle changes available to patients, even without psoriasis-specific clinical trial data confirming a direct skin-clearing effect.

As with other lifestyle factors discussed in this guide, exercise should be understood as a supportive measure rather than a treatment replacement. It works best as part of the broader, dermatologist-guided plan described throughout our pillar guide, not as a standalone strategy for moderate to severe disease.

How Treatment Targets Inflammation Directly

Understanding inflammation’s role in psoriasis explains, more than anything else, why modern treatment works the way it does. Nearly every effective psoriasis medication targets some point along the inflammatory pathways described above.

Why TNF-Alpha Became an Early Treatment Target

Some of the first biologic therapies for psoriasis targeted TNF-alpha specifically because of how clearly it was implicated in the inflammatory process. Therapeutic targeting of TNF-alpha with biologic agents such as etanercept, infliximab, and adalimumab has proven the important role of this mediator of inflammation in psoriasis, since blocking it produced measurable clinical improvement.

Why Newer Biologics Target IL-23 and IL-17 Instead

As covered in more detail in our pillar guide’s treatment section, newer biologic classes target cytokines positioned further along, or further upstream, in the inflammatory cascade. IL-23 activates Th17 cells to release IL-17A and IL-17F, which induce keratinocyte hyperactivation, making these specific cytokines highly precise, evidence-supported treatment targets rather than broad immune suppressants.

This precision is exactly why modern biologics tend to control inflammation more effectively, with fewer broad side effects, than older, less targeted systemic treatments. Understanding this inflammatory chain is what allows researchers to keep refining treatment, targeting the process closer and closer to its actual root cause.

Putting It All Together: A Realistic Framework

Bringing the inflammatory science together with practical guidance, a few conclusions stand out clearly from current research. None of these lifestyle factors substitute for medical treatment, but together they form a reasonable supporting framework.

Medical treatment remains the primary lever for controlling inflammation in moderate to severe psoriasis, given how directly modern biologics target the specific inflammatory pathways described above. Diet, sleep, and exercise are supportive, not primary, tools.

Weight management has the most consistent supporting evidence among lifestyle factors, likely because it directly reduces a genuine, measurable source of inflammatory activity in fat tissue. This makes it a reasonable, evidence-aligned priority for patients carrying excess weight.

Sleep deserves more attention than it typically receives, given the well-documented, bidirectional relationship between poor sleep and elevated inflammatory markers. Addressing sleep disruption is both a comfort issue and, plausibly, an inflammation-management issue.

Fish oil and specific supplements remain genuinely uncertain, and patients should be wary of confident claims in either direction. If considered, this should be discussed with a dermatologist, particularly given the broader supplement safety considerations discussed in our “Ashwagandha for Psoriasis” guide. For a full walkthrough of proven psoriasis treatment options, see our complete guide, “What Is Psoriasis? A Complete Guide to Causes, Symptoms, and Treatment.”

Frequently Asked Questions

1. Is psoriasis caused by inflammation, or does it cause inflammation?

Both, in a sense. An underlying immune dysfunction triggers the initial inflammatory response, and that same inflammation then perpetuates and worsens the disease, creating a self-sustaining cycle rather than a simple one-way cause and effect.

2. Can blood tests measure psoriasis-related inflammation?

Yes. Markers like CRP, ESR, and newer biomarkers such as YKL-40 can detect elevated systemic inflammation in psoriasis patients, though these tests are used more for research and monitoring comorbidity risk than for diagnosing psoriasis itself.

3. Does psoriasis inflammation ever fully go away?

Even when skin appears completely clear, some research suggests an underlying elevated immune “set-point” may persist, which could help explain why psoriasis often returns after treatment stops. This is part of why long-term, sustained treatment is generally recommended over stopping once skin clears.

4. Does an anti-inflammatory diet cure psoriasis?

No. While some evidence supports modest benefits from certain dietary patterns, particularly around weight management, no diet has been shown to cure or reliably control moderate to severe psoriasis on its own.

5. Should I take fish oil supplements for my psoriasis?

The evidence is genuinely mixed, with some trials showing benefit and others showing none, and effects that may depend heavily on dose and duration. This is worth discussing with your dermatologist rather than assuming it will help.

6. How does poor sleep affect psoriasis inflammation?

Poor sleep is associated with elevated levels of inflammatory markers like CRP and IL-6 in general population research, and psoriasis-related itching often disrupts sleep in the first place. This can create a reinforcing cycle where poor sleep and active inflammation feed into each other.

7. Why do newer psoriasis biologics target different molecules than older ones?

Research has identified increasingly specific inflammatory targets over time, moving from broader mediators like TNF-alpha toward more precise targets like IL-23 and IL-17. This precision generally allows for effective inflammation control with a more favorable side-effect profile.

8. Can exercise reduce psoriasis symptoms?

There’s no large, dedicated clinical trial proving exercise directly clears psoriasis plaques, but exercise supports weight management, which does have reasonably solid evidence for reducing psoriasis-related inflammation. It’s a reasonable, low-risk supportive measure alongside medical treatment.

9. Is systemic inflammation in psoriasis dangerous even without other symptoms?

Yes, potentially. Elevated inflammatory markers have been linked to subclinical cardiovascular changes and other comorbidities even before symptoms become noticeable, which is part of why routine comorbidity screening matters, as discussed in our pillar guide.

10. Does treating skin inflammation also reduce inflammation elsewhere in the body?

Effective systemic and biologic treatment appears to reduce circulating inflammatory markers as well as visible skin symptoms, based on current understanding of how these therapies work. This is part of the rationale behind the “psoriatic march” concept and the broader case for consistent, well-monitored treatment covered throughout our pillar guide.

Sources and References

“Psoriasis as a Systemic Inflammatory Disease: An Immune Set-Point Framework for Comorbidities and Relapse,” Frontiers in Immunology, 2026.
“Skin Immune Microenvironment in Psoriasis: From Bench to Bedside,” Frontiers in Immunology, 2025.
Mleczko M., Gerkowicz A., Krasowska D., “Chronic Inflammation as the Underlying Mechanism of the Development of Lung Diseases in Psoriasis: A Systematic Review,” International Journal of Molecular Sciences, PMC, 2022.
“Role of Innate Immune Cells in Psoriasis,” PMC.
Schön M.P., “Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders,” Frontiers in Immunology, PMC, 2019.
“Pellino1 Promotes Chronic Inflammatory Skin Disease via Keratinocyte Hyperproliferation and Induction of the T Helper 17 Response,” PMC.
“Innate and Adaptive Immunity and the Pathophysiology of Psoriasis,” Journal of the American Academy of Dermatology, PubMed, 2006.
“The Effect of Antioxidant and Anti-Inflammatory Capacity of Diet on Psoriasis and Psoriatic Arthritis Phenotype: Nutrition as Therapeutic Tool?” PMC, 2021.
“Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis,” PMC.
“Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients,” PMC.
“The Relationship Between Sleep and Salivary and Serum Inflammatory Biomarkers in Adolescents,” PMC, 2023.
“Effects of Exercise on Brain and Peripheral Inflammatory Biomarkers Induced by Total Sleep Deprivation in Rats,” PMC.
Yang S-J., Chi C-C., “Effects of Fish Oil Supplement on Psoriasis: A Meta-Analysis of Randomized Controlled Trials,” BMC Complementary Medicine and Therapies, 2019.
Huang et al., “The Effects of Fatty Acids on Psoriasis: A Two-Sample Mendelian Randomization Study,” Journal of Cosmetic Dermatology, Wiley, 2024.
“Fish Oil Supplements for Treatment of Psoriasis: An Overview of Systematic Reviews,” Dermatologica Sinica, Wolters Kluwer, 2024.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6896351/

This article is intended for general educational purposes and does not replace personalized medical advice. Anyone with psoriasis should consult a board-certified dermatologist before making significant changes to diet, supplementation, or treatment based on inflammation-related research.